Cyclin D1 is overexpressed in half of breast cancer cases. This research indicates that BRCA1 suppresses Cyclin D1 activation of ERa, an estrogen sensitive receptor. In breast cancer, BRCA1 is inactivated and Cyclin D1 is free to upregulate ERa. Therefore, Cyclin D1 is a great drug target.
Wang, C et al 2005: Cyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor alpha Activity
Did this article help you?
If you found this piece useful, please consider supporting our work with a small, one-time or monthly donation. Your contribution enables us to continue bringing you accurate, thought-provoking science and medical news that you can trust. Independent reporting takes time, effort, and resources, and your support makes it possible for us to keep exploring the stories that matter to you. Together, we can ensure that important discoveries and developments reach the people who need them most.